163 related articles for article (PubMed ID: 12131781)
1. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Shiratori K; Takeuchi T; Satake K; Matsuno S;
Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
[TBL] [Abstract][Full Text] [Related]
2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Nakano S; Kihara Y; Otsuki M
Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan.
Ochi K; Harada H; Satake K
Digestion; 1999; 60 Suppl 1():81-5. PubMed ID: 10026438
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
Nakano S; Tachibana I; Otsuki M
Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
[TBL] [Abstract][Full Text] [Related]
5. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
[TBL] [Abstract][Full Text] [Related]
6. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
[TBL] [Abstract][Full Text] [Related]
7. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
[TBL] [Abstract][Full Text] [Related]
8. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
Otsuki M; Nakano S; Tachibana I
Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
[TBL] [Abstract][Full Text] [Related]
9. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
Imoto I; Yamamoto M; Jia DM; Otsuki M
Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
[TBL] [Abstract][Full Text] [Related]
12. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
13. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.
Militello C; Sperti C; Di Prima F; Pedrazzoli S
Pancreas; 1997 Apr; 14(3):222-8. PubMed ID: 9094151
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
Satake K; Kimura K; Saito T
Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435
[TBL] [Abstract][Full Text] [Related]
16. Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis.
Leonhardt U; Seidensticker F; Fussek M; Stöckmann F; Creutzfeldt W
Int J Pancreatol; 1991 Sep; 10(1):73-80. PubMed ID: 1757732
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
18. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
Schmidt WE; Creutzfeldt W; Schleser A; Choudhury AR; Nustede R; Höcker M; Nitsche R; Sostmann H; Rovati LC; Fölsch UR
Am J Physiol; 1991 Feb; 260(2 Pt 1):G197-206. PubMed ID: 1996640
[TBL] [Abstract][Full Text] [Related]
19. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
[TBL] [Abstract][Full Text] [Related]
20. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
Fried M; Erlacher U; Schwizer W; Löchner C; Koerfer J; Beglinger C; Jansen JB; Lamers CB; Harder F; Bischof-Delaloye A
Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
